Ubs Group Ag Biocryst Pharmaceuticals Inc Transaction History

Ubs Group Ag

$452 Billion
Q3 2024

A detailed history of Ubs Group Ag transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Ubs Group Ag holds 8,000 shares of BCRX stock, worth $60,560. This represents 0.0% of its overall portfolio holdings.

Number of Shares

8,000

Previous 8,000 -0.0%

Holding current value

$60,560

Previous $49,000 22.45%

% of portfolio

0.0%

Previous 0.0%

31 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$6.41 - $8.69 $214,952 - $291,410	33,534 Added 8.57%	425,019 $3.23 Million
Q2 2024 Aug 13, 2024	SELL	$4.13 - $6.79 $2.5 Million - $4.11 Million	-605,070 Reduced 60.72%	391,485 $2.42 Million
Q1 2024 May 13, 2024	BUY	$4.89 - $7.65 $1.52 Million - $2.38 Million	311,567 Added 45.49%	996,555 $5.06 Million
Q4 2023 Feb 09, 2024	BUY	$4.98 - $6.77 $1.89 Million - $2.57 Million	379,037 Added 123.89%	684,988 $4.1 Million
Q3 2023 Nov 09, 2023	SELL	$6.71 - $7.92 $730,604 - $862,353	-108,883 Reduced 26.25%	305,951 $2.17 Million
Q2 2023 Aug 11, 2023	BUY	$6.96 - $8.81 $62,319 - $78,884	8,954 Added 2.21%	414,834 $2.92 Million
Q1 2023 May 12, 2023	SELL	$7.94 - $11.84 $1.7 Million - $2.53 Million	-213,548 Reduced 34.48%	405,880 $3.39 Million
Q4 2022 Feb 08, 2023	BUY	$10.5 - $14.2 $4.62 Million - $6.25 Million	439,894 Added 245.02%	619,428 $7.11 Million
Q3 2022 Nov 10, 2022	BUY	$10.79 - $14.81 $292,365 - $401,291	27,096 Added 17.78%	179,534 $2.26 Million
Q2 2022 Aug 10, 2022	BUY	$7.89 - $17.88 $73,298 - $166,105	9,290 Added 6.49%	152,438 $1.61 Million
Q1 2022 May 16, 2022	SELL	$11.56 - $19.76 $4.5 Million - $7.7 Million	-389,502 Reduced 73.13%	143,148 $2.33 Million
Q4 2021 Feb 14, 2022	BUY	$11.18 - $15.46 $2.17 Million - $3 Million	194,262 Added 57.41%	532,650 $7.38 Million
Q3 2021 Nov 15, 2021	BUY	$14.21 - $17.65 $2.26 Million - $2.81 Million	159,369 Added 89.02%	338,388 $4.86 Million
Q2 2021 Aug 13, 2021	SELL	$9.5 - $17.24 $98,771 - $179,244	-10,397 Reduced 5.49%	179,019 $2.83 Million
Q1 2021 May 12, 2021	SELL	$7.37 - $13.61 $2.49 Million - $4.61 Million	-338,457 Reduced 64.12%	189,416 $1.93 Million
Q4 2020 Feb 11, 2021	SELL	$3.37 - $8.61 $3.06 Million - $7.83 Million	-909,182 Reduced 63.27%	527,873 $3.93 Million
Q3 2020 Nov 12, 2020	BUY	$3.43 - $5.53 $4.38 Million - $7.07 Million	1,278,179 Added 804.51%	1,437,055 $4.94 Million
Q2 2020 Jul 31, 2020	SELL	$1.9 - $5.61 $9.36 Million - $27.6 Million	-4,924,362 Reduced 96.87%	158,876 $757,000
Q1 2020 May 01, 2020	SELL	$1.6 - $4.11 $648,078 - $1.66 Million	-405,049 Reduced 7.38%	5,083,238 $10.2 Million
Q4 2019 Feb 14, 2020	BUY	$1.59 - $3.45 $3.9 Million - $8.45 Million	2,450,478 Added 80.67%	5,488,287 $18.9 Million
Q3 2019 Nov 14, 2019	BUY	$2.5 - $3.73 $2.09 Million - $3.11 Million	835,015 Added 37.91%	3,037,809 $8.7 Million
Q2 2019 Aug 14, 2019	BUY	$2.91 - $9.15 $4.92 Million - $15.5 Million	1,691,681 Added 330.98%	2,202,794 $8.35 Million
Q1 2019 May 14, 2019	BUY	$7.38 - $9.72 $2.85 Million - $3.75 Million	385,569 Added 307.12%	511,113 $4.16 Million
Q4 2018 Feb 14, 2019	BUY	$6.51 - $9.6 $88,920 - $131,126	13,659 Added 12.21%	125,544 $1.01 Million
Q3 2018 Nov 14, 2018	BUY	$5.52 - $7.99 $268,525 - $388,681	48,646 Added 76.92%	111,885 $854,000
Q2 2018 Aug 14, 2018	SELL	$4.6 - $6.52 $1.05 Million - $1.49 Million	-228,140 Reduced 78.3%	63,239 $362,000
Q1 2018 May 15, 2018	BUY	$4.35 - $5.82 $831,532 - $1.11 Million	191,157 Added 190.73%	291,379 $1.39 Million
Q4 2017 Feb 14, 2018	SELL	$4.16 - $5.33 $57,790 - $74,044	-13,892 Reduced 12.17%	100,222 $493,000
Q3 2017 Nov 14, 2017	BUY	$4.1 - $5.97 $207,603 - $302,290	50,635 Added 79.77%	114,114 $598,000
Q2 2017 Aug 14, 2017	SELL	N/A	-8,562 Reduced 11.88%	63,479 $353,000
Q1 2017 Nov 14, 2017	BUY	N/A	72,041	72,041 $605,000

Others Institutions Holding BCRX

# of Institutions

278

Shares Held

172M

Call Options Held

625K

Put Options Held

739K

View Full List

About BIOCRYST PHARMACEUTICALS INC

Ticker BCRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,944,992
Market Cap $1.41B
Description
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...

More about BCRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account